Please login to order a test.
Cancer Antigen (CA) 125 in the Presence of Human Antimouse Antibodies (HAMA)
- CA-125 in the Presence of HAMA
Eliminate interference from HAMA in the CA 125 assay to help monitor disease progression in nonmucinous epithelial neoplasms of the ovary. This test is performed in the same way as the Cancer Antigen (CA) 125 test except that the interference from HAMA present in the specimen is eliminated by use of a blocking reagent.
CA 125 is not specific for tumors of the ovary and cannot distinguish benign from malignant tumors. It is not a screening test.
Electrochemiluminescence immunoassay (ECLIA)
• Female: 0.0−38.1 units/mL
• Male: Not established
0.5 mL (Note: This volume does not allow for repeat testing.)
Red-top tube or gel-barrier tube
It is suggested that the assay not be performed until at least three weeks after the completion of primary chemotherapy and at least two months following abdominal surgery.
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Room temperature; stable at room temperature or refrigerated for 14 days.
Causes for Rejection
Citrate plasma specimen; improper labeling
A blocking agent is used to remove interference from HAMA (human antimouse antibodies) in the CA 125 assay. For a complete test description, see Cancer Antigen (CA) 125 .
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|144733||CA 125 in the Presence of HAMA||10334-1||144738||CA 125 in the Presence of HAMA||U/mL||10334-1|